Acetaminophen and prostate cancer
Aspirin is the oldest member of a large group of nonsteroidal anti-inflammatory drugs (NSAIDs). Aspirin is also the safest of these drugs, since it's the only member of the group that does not increase the risk of heart attack and stroke. And a meta-analysis of 17 studies of aspirin linked the drug to a 17% reduction in the risk of prostate cancer. Other research suggests that various nonaspirin NSAIDs are also capable of reducing the risk of cancer. Twelve studies of nonaspirin NSAIDs reported a 10% reduction in the risk of prostate cancer.
To continue reading this article, you must log in.
Source matters. Subscribe to HarvardHealthOnline+ FREE for 30 days for unlimited access to the site – where all content is reviewed by an HMS physician or faculty expert.
With HHO+ you get these exclusive benefits:
- Unlimited access to all Harvard Health Online content
- 4 expertly curated newsletters delivered monthly
- Customized website experience aligned to your health goals
- In-depth health guides on topics like sleep, exercise, and more
- Interactive features like videos and quizzes
- Members-only access to exclusive articles and resources
SPECIAL OFFER! UNLOCK EXPERT ACCESS for 30 days FREE!
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
